Table 2.
Predictors of daytime SpO2 in SCA.
| Explanatory variable | β-coefficient | P value | Adj r 2 |
|---|---|---|---|
| Hematological indices | |||
| Hemoglobin (g/dL) | 0.35 | 0.007 | 0.014 |
| RBC × 10−9 | 1.10 | <0.001 | 0.050 |
| MCHC (g/dL) | −0.57 | <0.001 | 0.073 |
| MCH | −0.29 | <0.001 | 0.090 |
| MCV (fl) | −0.02 | 0.041 | 0.007 |
| HbF% (N = 315)† | 0.12 | <0.001 | 0.026 |
| Iron status and nutritional status | |||
| Transferrin saturation % | −0.03 | 0.03 | 0.008 |
| BMI Z-score (N = 451) | 0.18 | 0.049 | 0.006 |
| Hemolytic markers | |||
| Lactate dehydrogenase (IU) {natural log} (N = 427) | −0.72 | 0.011 | 0.013 |
| Unconjugated bilirubin (μmol/L) {natural log} (N = 415) | −0.34 | 0.029 | 0.009 |
| α-thalassemia genotype | |||
| 3.7 heterozygote versus Wild Type | 1.29 | <0.001 | |
| 3.7 homozygote versus Wild Type | 2.04 | <0.001 | 0.056* |
| G6PD genotype | |||
| Heterozygote females versus Wild Type | −0.52 | 0.276 | |
| Homozygote females and affected males versus Wild Type | −1.30 | 0.005 | 0.014* |
N = 458 unless otherwise stated. *Adj r 2 for whole model. †Analysis of SpO2 limited to those with HbF and SpO2 measured when patients were 5 years or older.